MENU
+Compare
ALLO
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$2.17
Change
-$0.09 (-3.98%)
Capitalization
454.99M

ALLO Allogene Therapeutics Forecast, Technical & Fundamental Analysis

a developer of allogeneic chimeric antigen receptor therapy

Industry Biotechnology
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ALLO with price predictions
Feb 21, 2025

ALLO's Indicator enters downward trend

The Aroon Indicator for ALLO entered a downward trend on February 14, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 307 similar instances where the Aroon Indicator formed such a pattern. In of the 307 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ALLO moved out of overbought territory on February 20, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ALLO broke above its upper Bollinger Band on February 18, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where ALLO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on February 14, 2025. You may want to consider a long position or call options on ALLO as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ALLO just turned positive on February 14, 2025. Looking at past instances where ALLO's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

ALLO moved above its 50-day moving average on February 14, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +10 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in of 255 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALLO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.981) is normal, around the industry mean (12.496). P/E Ratio (0.000) is within average values for comparable stocks, (84.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). ALLO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). ALLO's P/S Ratio (10000.000) is very high in comparison to the industry average of (251.218).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ALLO is expected to report earnings to rise 1.41% to -32 cents per share on February 26

Allogene Therapeutics ALLO Stock Earnings Reports
Q4'24
Est.
$-0.32
Q3'24
Beat
by $0.01
Q2'24
Est.
$-0.35
Q1'24
Beat
by $0.03
Q4'23
Missed
by $0.06
The last earnings report on November 07 showed earnings per share of -31 cents, beating the estimate of -33 cents. With 4.88M shares outstanding, the current market capitalization sits at 454.99M.
A.I. Advisor
published General Information

General Information

a developer of allogeneic chimeric antigen receptor therapy

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
210 East Grand Avenue
Phone
+1 650 457-2700
Employees
233
Web
https://www.allogene.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FLACX79.81N/A
N/A
Fidelity Advisor Stock Sel C
UPUPX11.93N/A
N/A
Upright Growth
GLVYX88.31N/A
N/A
Invesco Global Focus Y
JSGTX28.85N/A
N/A
JHancock U.S. Growth R6
HDAVX16.58-0.04
-0.24%
Janus Henderson Responsible Intl Div A

ALLO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with FATE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
-3.77%
FATE - ALLO
57%
Loosely correlated
-8.09%
CRSP - ALLO
56%
Loosely correlated
-5.00%
NTLA - ALLO
55%
Loosely correlated
-0.65%
PRME - ALLO
50%
Loosely correlated
-5.27%
BEAM - ALLO
49%
Loosely correlated
-8.18%
More